Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)

Pfizer

Status and phase: Completed; Phase 3

Conditions: Macular Degeneration

Treatments: Drug: pegaptanib sodium

Study type: Interventional

Funder types: Industry

Identifiers

NCT00150202

A5751010

Details and patient eligibility

About

This study will examine the efficacy and safety of pegaptanib sodium in Japanese patients with wet-type AMD, in order to establish that there is no large difference in the efficacy and the safety of the drug between Western and Japanese patients.

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Wet AMD, Visual Acuity from 20/320 to 20/40

Exclusion criteria

• Diabetic retinopathy, laser coagulation history

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind